Electron-capture GLC determination of a new antiarrhythmic agent, alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl) benzylamine, in biological fluids.
A highly specific and sensitive GLC method was developed for the analysis of alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl) benzylamine, a new orally active antiarrhythmic drug, in biological fluids. The procedure involves the addition of an internal standard, 4-(alpha,alpha,beta,beta-tetrafluorophenethyl)benzylamine, to the plasma or urine samples followed by extraction of the drugs into benzene at pH 8. The extracted amines are converted to the trifluoroacetyl derivatives (characterized by GLG-mass spectrometry), chromatographed, and detected with a 63Ni electron-capture detector. The sensitivity of the method is such that 10 ng of alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl)benzylamine/ml of plasma can be analyzed. These levels are suitable for the analysis of samples obtained following a therapeutic dose.